February 17, 2021
FEBRUARY 2021 Jordan Messler, MD, SFHM, FACP Why the Pandemic Sparked Improvement in Real-time Patient Dashboards The implementation of Electronic Health Records (EHR) following the government mandate more than a decade ago hasn’t always been easy, but it can be a game-changer when it comes to real-time patient data management. While EHRs drastically simplify the access to patient-specific data, information …
May 16, 2019
The company’s growing intellectual property portfolio attests to its leadership position in diabetes medication optimization in an era of data-driven care.
Glytec, the pioneer of digital therapeutics, has been awarded another patent allowance by the United States Patent and Trademark Office (USPTO). The latest allowance references interactions between the company’s software-as-a-medical-device platform for insulin titration and multiple connected diabetes technologies, including continuous glucose monitoring (CGM) systems, smart insulin pens and insulin pumps.
May 14, 2019
The May 30, 2019 webinar will explore the keys to augmenting traditional brick-and-mortar care with virtual care for people with diabetes.
Managing the care of people with diabetes is costly and time intensive, especially for our nation’s primary care providers who shoulder 80% of that responsibility. Virtual care programs have the potential to fill critical gaps and meet increasing demands, but can they produce real results?
March 27, 2019
The Dario® Blood Glucose Monitoring System will be made available to hospitals and health systems using Glytec’s virtual insulin titration service for outpatients with diabetes.
Global digital therapeutics innovator, DarioHealth Corp. (Nasdaq: DRIO), today announced a joint marketing agreement with Glytec, the market leader and pioneer of insulin titration solutions for use across the full continuum of care. The agreement allows DarioHealth’s smart glucose meter (part of the Dario Blood Glucose Monitoring System) to transmit information to Glytec’s Glucommander™ Outpatient software-as-a-medical-device.
August 29, 2018
The newest USPTO allowances describe an integrated, connected care model for optimizing insulin therapy in the outpatient setting.
The United States Patent and Trademark Office has awarded Glytec two more patent allowances acknowledging the unique characteristics of its disruptive innovations. The allowances, which comprise a total of 52 claims, describe interactions between Glytec’s solution for insulin titration and multiple current and future-state connected diabetes technologies and health information systems, including devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.
June 6, 2018
The iGlucose® Cell-Enabled Diabetes Care Solution from Smart Meter is now compatible with Glytec’s virtual insulin titration service.
For millions of patients with diabetes who’ve been unable to achieve their treatment goals, few programs have the potential to reduce A1C faster or more effectively than Glytec’s virtual insulin titration service. The innovative service harnesses the integration of Glytec’s Glucommander™ Outpatient software with multiple connected diabetes technologies and health information systems, including those for blood glucose measurement, insulin delivery, medical record keeping and patient communication, among others. The latest company to join Glytec’s network of connected solution partners is Smart Meter, LLC, maker of the iGlucose® Cell-Enabled Diabetes Care Solution, bringing timely, complete and accurate data to insulin titration.
February 15, 2018
New study in which insulin dosing was guided by Glytec’s Glucommander™ Outpatient observed markedly greater reductions in A1c among patients who tested blood glucose twice a day or more.
A retrospective study being presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) observed that use of Glytec’s Glucommander™ Outpatient for insulin therapy management combined with blood glucose self-testing at least twice a day resulted in better patient outcomes, including a 3.0% absolute reduction in A1c and virtually no hypoglycemia (0.003%) less than 54 mg/dL.
January 5, 2018
The allowed patent encompasses detailed interactions between multiple connected diabetes technologies.
Glytec, the pioneer of personalized digital therapeutics, has been awarded another U.S. patent allowance for systems and methods related to insulin management in the outpatient environment. The new patent allowance comprises 30 individual claims describing a connected care model that harnesses the integration of Glytec’s software-as-a-medical-device for insulin titration with multiple current- and future-state connected diabetes technologies and health information systems, including any and all devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.
November 29, 2017
The integrated solution will launch in pilot programs with select U.S. providers and payers early 2018.
Glytec is pleased to announce its Glucommander™ Outpatient will be integrated with Onduo’s virtual diabetes clinic to help people with type 2 diabetes more easily manage insulin therapy and achieve their glucose targets. Onduo, a joint venture of Sanofi and Verily (an Alphabet company), is developing a virtual platform that integrates hardware, such as wirelessly-connected continuous glucose monitors, software and personalized support from healthcare experts to help people manage their type 2 diabetes. The integrated solution will launch in pilot programs with select U.S. providers and payers early 2018.
September 19, 2017
A study presented at EASD 2017 shows long-term A1C reductions through personalized insulin dose adjustments every eight weeks using Glytec’s therapy management software.
More than 50 percent of all people using insulin to manage diabetes are not at their target A1C, which is why this high-risk population is a primary focus of value-based care strategies among providers and payers alike. A retrospective study presented at the Annual Meeting of the European Association for the Study of Diabetes shows that patients whose insulin therapy is guided by Glytec’s FDA-cleared Glucommander™ software not only achieve glucose control rapidly, but with ongoing personalized dose adjustments, successfully maintain A1C reductions long term.
August 18, 2017
Diabetes educators learned how Glytec’s software and other data-driven technologies help overcome key challenges of insulin management.
A presentation on diabetes decision support solutions at this year’s American Association of Diabetes Educators (AADE) conference showcased how use of Glytec’s therapy management software in conjunction with connected device systems is breaking down barriers to effective and timely insulin management and, as a result, reducing the risks and costs of diabetes for providers, payers and patients alike.
July 24, 2017
Data-sharing capabilities are important for faster communications and results that can greatly benefit the patient, says Robby Booth, senior vice president of research and development at Glytec.
Over the past few months, there have been some announcements that we’ve made. We have a partnership now with AgaMatrix, which is a Bluetooth glucose meter, to be able to capture their data from the cloud. We have a partnership with Livongo, which is a cellular meter, so we can capture that data from their cloud; and we have a partnership with Telcare, which is also a cellular meter.
June 29, 2017
Poised to address diabetes on a global scale, the company expands its intellectual property protections in the United States and abroad.
Glytec, the healthcare company behind a market-leading software solution for personalized diabetes therapy management, announces five new patent allowances for its eGlycemic Management System® (eGMS®), increasing the company’s portfolio to a total of 11 allowed or issued patents, with more than 50 pending.
June 8, 2017
AgaMatrix, Inc. and Glytec announced today they are partnering to optimize clinical access to accurate glucose data and insulin titration support through a cloud-based diabetes management platform.
AgaMatrix is integrating their FDA-cleared Jazz Wireless 2 Bluetooth® Blood Glucose Monitoring System with Glytec’s eGlycemic Management System® (eGMS®), featuring FDA-cleared Glucommander™ for evidence-based insulin dosing decision support. By automatically transferring patient blood glucose data from the AgaMatrix Diabetes Manager App to eGMS®, health care professionals are able to deliver personalized diabetes therapy management in a virtual setting. The two companies are actively engaged in a pilot of this integrated solution.
April 18, 2017
Livongo goes deeper into medication optimization.
Livongo Health, the leading consumer digital health company focused on empowering people with chronic conditions to live better and healthier lives, today announced a partnership with Glytec to offer eGlycemic Management System®, or eGMS®, to Livongo members. With this alliance, Livongo and Glytec will partner to deliver an expanded diabetes management solution that includes insulin titration, making managing diabetes easier for members and their providers.
April 10, 2017
The healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
Diabetes therapy management software with decision support for dosing and titration is the final piece of the therapeutic puzzle. In concert with data made available through CGM and cBGM, this software can help providers properly dose and titrate diabetes medications, especially insulin, and choose which diabetes medications may work best for each patient. Diabetes therapy management software, in its earliest form, was launched by Glytec in 2006.
December 15, 2016
This latest notice of allowance from the United States Patent and Trademark Office deepens Glytec’s intellectual property protections and further validates its leadership stature in the healthcare market.
Glytec today announces another notice of allowance from the United States Patent and Trademark Office (USPTO) for its eGlycemic Management System® (eGMS®), a modularized software-as-a-service solution used by hospitals and health systems for personalized insulin dosing, enterprise glucose surveillance, performance-driven analytics, and more. This latest notice comes on the heels of three others received this past September — adding to U.S. Patent 9,233,204 and U.S. Patent 9,171,343 — bringing the total number of patents held by Glytec to six, with more than 50 U.S. and international patents pending.
September 27, 2016
The notices further validate Glytec’s position as a leader in advanced technologies and innovations for glycemic management.
The company is aggressively building a patent portfolio that affords protection of its proprietary diabetes technologies. The three new allowances will issue as patents over the next 60 days — adding to U.S. Patent 9,233,204 and U.S. Patent 9,171,343 — bringing the total number of patents held by Glytec to five. The company has more than 30 other U.S. and international patent applications pending.
November 9, 2015
A software system called Glucommander from Glytec Systems works well at titrating the right dose to bring blood sugar levels under control.
The company has now released results of a 30-day study for outpatients using the system in their homes. The subjects were given a glucometer that transmits data readings using a cellular data connection. The Glucommander system would then send the recommended dosage to the patient as a text message. The results of the test showed that 90% of the subjects in the study were able to achieve their target levels within three weeks.
November 3, 2015
Ninety percent of study participants achieved target glucose within 3 weeks and achieved an average reduction in estimated A1C of 3.0%.
Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that Glucommander™, a component of the company’s eGMS® platform, achieved its 30-day primary efficacy endpoint in a study evaluating the average A1C reduction in an outpatient setting for persons with type 1 and type 2 diabetes. According to study results, Glucommander was effective at titrating insulin doses and quickly achieving glucose control, with low rates of hypoglycemia, for 22 patients, regardless of the severity of their diabetes. The average starting A1C was 10.4% and the average estimated A1C (eA1C) at 30-days was 7.4%.
